Literature DB >> 20039791

Clozapine and cardiometabolic health in chronic schizophrenia: correlations and consequences in a clinical context.

Gin Malhi1, Danielle Adams, Janice Plain, Carissa Coulston, Michael Herman, Garry Walter.   

Abstract

OBJECTIVE: The aim of this study was to identify the prevalence of metabolic syndrome and its putative precursors in a naturalistic study of non-acute inpatients at a psychiatric hospital.
METHOD: Anthropometric and biochemical data collected from the hospital's annual cardiometabolic survey, along with information about prescribed medications, were used to assess the prevalence and predictors of physical health problems in patients with schizophrenia.
RESULTS: Of the 167 patients included in the survey, 52.4% met criteria for metabolic syndrome. A shorter duration of hospital admission and clozapine use were significant predictors of metabolic syndrome. Age, gender, duration of admission and clozapine use were all predictors of individual cardiometabolic risk factors.
CONCLUSIONS: The findings from this naturalistic study reinforce the high prevalence of physical health problems in patients with schizophrenia and the important influence that psychiatric treatments can have on physical health. The impact of clozapine on cardiometabolic health appears to occur early in the course of treatment and emphasizes the need for proactive monitoring and interventions from the outset of management.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20039791     DOI: 10.3109/10398560903254193

Source DB:  PubMed          Journal:  Australas Psychiatry        ISSN: 1039-8562            Impact factor:   1.369


  4 in total

Review 1.  Adverse effects of clozapine in older patients: epidemiology, prevention and management.

Authors:  Delia Bishara; David Taylor
Journal:  Drugs Aging       Date:  2014-01       Impact factor: 3.923

2.  A case report of the successful administration of clozapine in the face of myocardial infarction, pulmonary embolism and hyperlipidaemia resulting in the termination of long-term seclusion.

Authors:  Alex Till; Ed Silva
Journal:  BMC Psychiatry       Date:  2019-01-23       Impact factor: 3.630

3.  Improving metabolic and cardiovascular health at an early psychosis intervention program in vancouver, Canada.

Authors:  Diane H Fredrikson; Heidi N Boyda; Lurdes Tse; Zachary Whitney; Mark A Pattison; Fred J Ott; Laura Hansen; Alasdair M Barr
Journal:  Front Psychiatry       Date:  2014-09-05       Impact factor: 4.157

4.  Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile.

Authors:  Renato de Filippis; Raffaele Gaetano; Georgios Schoretsanitis; Giuseppe Verde; Cesare Anthony Oliveti; John M Kane; Cristina Segura-Garcia; Pasquale De Fazio
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-01       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.